531 related articles for article (PubMed ID: 35305726)
1. Natural killer cell-based strategies for immunotherapy of cancer.
Vaněk O; Kalousková B; Abreu C; Nejadebrahim S; Skořepa O
Adv Protein Chem Struct Biol; 2022; 129():91-133. PubMed ID: 35305726
[TBL] [Abstract][Full Text] [Related]
2. Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer.
Obajdin J; Davies DM; Maher J
Clin Exp Immunol; 2020 Oct; 202(1):11-27. PubMed ID: 32544282
[TBL] [Abstract][Full Text] [Related]
3. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
Front Immunol; 2019; 10():2683. PubMed ID: 31798595
[TBL] [Abstract][Full Text] [Related]
4. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
6. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
7. Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C; Hu Y; Shi C
Front Immunol; 2020; 11():60. PubMed ID: 32140153
[TBL] [Abstract][Full Text] [Related]
8. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
Kennedy PR; Felices M; Miller JS
Stem Cell Res Ther; 2022 Apr; 13(1):165. PubMed ID: 35414042
[TBL] [Abstract][Full Text] [Related]
9. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
[TBL] [Abstract][Full Text] [Related]
10. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
11. Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy.
Zhang J; Zheng H; Diao Y
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646574
[TBL] [Abstract][Full Text] [Related]
12. The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells.
Moscarelli J; Zahavi D; Maynard R; Weiner LM
Transplant Cell Ther; 2022 Oct; 28(10):650-656. PubMed ID: 35788086
[TBL] [Abstract][Full Text] [Related]
13. NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells.
Zhuang X; Long EO
Front Immunol; 2022; 13():840844. PubMed ID: 35585985
[TBL] [Abstract][Full Text] [Related]
14. CAR-NK cells for cancer immunotherapy: recent advances and future directions.
Li T; Niu M; Zhang W; Qin S; Zhou J; Yi M
Front Immunol; 2024; 15():1361194. PubMed ID: 38404574
[TBL] [Abstract][Full Text] [Related]
15. Driving natural killer cell-based cancer immunotherapy for cancer treatment: An arduous journey to promising ground.
Jiang D; Zhang J; Mao Z; Shi J; Ma P
Biomed Pharmacother; 2023 Sep; 165():115004. PubMed ID: 37352703
[TBL] [Abstract][Full Text] [Related]
16. Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment.
Portillo AL; Monteiro JK; Rojas EA; Ritchie TM; Gillgrass A; Ashkar AA
Front Immunol; 2023; 14():1286750. PubMed ID: 38022679
[TBL] [Abstract][Full Text] [Related]
17. [Research Progress of Chimeric Antigen Receptor Modified NK Cells in the Treatment of Acute Myeloid Leukemia --Review].
Peng XR; Cheng J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1905-1909. PubMed ID: 38071081
[TBL] [Abstract][Full Text] [Related]
18. Development of NK cell-based cancer immunotherapies through receptor engineering.
Page A; Chuvin N; Valladeau-Guilemond J; Depil S
Cell Mol Immunol; 2024 Apr; 21(4):315-331. PubMed ID: 38443448
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.
Fantini M; Arlen PM; Tsang KY
Front Immunol; 2023; 14():1275904. PubMed ID: 38077389
[TBL] [Abstract][Full Text] [Related]
20. Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy.
Choi C; Finlay DK
Stem Cell Res Ther; 2021 Jun; 12(1):320. PubMed ID: 34090499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
